2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016, 40: 468-475. PMID: 27659408, PMCID: PMC5360291, DOI: 10.2337/dc16-0985.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinLogistic ModelsMaleMetforminMiddle AgedRetrospective StudiesSulfonylurea CompoundsThiazolidinedionesYoung AdultConceptsGlycemic controlSevere hypoglycemiaOlder patientsDipeptidyl peptidase-4 inhibitorsGlucose-lowering drugsGlucose-lowering medicationsProportion of patientsOverall glycemic controlPeptidase-4 inhibitorsMedicare Advantage patientsSex-standardized ratesType 2 diabetesOverall rateClass of agentsMore comorbiditiesChronic comorbiditiesYounger patientsAdvantage patientsDrug utilizationClaims dataPatientsHypoglycemiaHemoglobin AT2DMComorbidities
2012
State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning
Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs 2012, 31: 188-198. PMID: 22232110, PMCID: PMC3319744, DOI: 10.1377/hlthaff.2011.1068.Peer-Reviewed Original ResearchMeSH KeywordsGatekeepingHumansHypoglycemic AgentsMedicaidPrescriptionsRosiglitazoneState GovernmentThiazolidinedionesUnited StatesConceptsState Medicaid programsPreferred drugDrug listPrior authorizationMedicaid programSafety warningsPrior authorization programHigh-cost drugsDiabetes medicationsPrescribing ratesEffective prescribingSafe prescribingMedicaid beneficiariesDiabetes drugsPrescribingState MedicaidHeart attackRosiglitazoneDrug availabilityDrugsAuthorization programPrescriptionMinimal changesMedicationsProviders
2010
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone. New England Journal Of Medicine 2010, 363: 2081-2084. PMID: 21083379, DOI: 10.1056/nejmp1011042.Peer-Reviewed Original ResearchLicensing drugs for diabetes
Lehman R, Yudkin JS, Krumholz H. Licensing drugs for diabetes. The BMJ 2010, 341: c4805. PMID: 20819887, DOI: 10.1136/bmj.c4805.Peer-Reviewed Original ResearchA Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks
Krumholz HM. A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks. Circulation Cardiovascular Quality And Outcomes 2010, 3: 221-222. PMID: 20181986, DOI: 10.1161/circoutcomes.110.936070.Peer-Reviewed Original Research
2005
Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction
Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM. Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction. Diabetes Care 2005, 28: 1680-1689. PMID: 15983320, DOI: 10.2337/diacare.28.7.1680.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionYear of dischargeHeart failureAntihyperglycemic agentsMyocardial infarctionHigh riskDiabetic patientsInsulin sensitizersMultivariable Cox proportional hazards modelsCox proportional hazards modelBorderline higher riskOlder diabetic patientsRetrospective cohort studyHeart failure readmissionInsulin-sensitizing drugsProportional hazards modelFirst rehospitalizationCause readmissionCohort studySecondary outcomesDischarge prescriptionsPrimary outcomeMultivariable analysisAntihyperglycemic drugsIndependent associationThiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure
Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure. Circulation 2005, 111: 583-590. PMID: 15699279, DOI: 10.1161/01.cir.0000154542.13412.b1.Peer-Reviewed Original ResearchConceptsHeart failureInsulin-sensitizing drugsOlder patientsLower riskCox proportional hazards modelAntidiabetic drug prescriptionRetrospective cohort studyPrincipal discharge diagnosisClustering of patientsProportional hazards modelCohort studySecondary outcomesPrimary outcomeMetformin treatmentRandomized trialsThiazolidinedione treatmentDischarge diagnosisInsulin sensitizersAdverse outcomesDrug prescriptionsMultivariable modelObservational studyHospital variablesThiazolidinedione classHigh risk
2003
Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure
Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM. Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. JAMA 2003, 290: 81-85. PMID: 12837715, DOI: 10.1001/jama.290.1.81.Peer-Reviewed Original ResearchConceptsHeart failureDiabetic patientsConcomitant diabetesThiazolidinedione useMedicare beneficiariesRetrospective medical record abstractionUse of metforminAdvanced heart failureProportion of patientsHeart failure therapyMedical record abstractionAcute care hospitalsMetformin useFailure therapyHospital dischargeCare hospitalRecord abstractionOptimal carePrimary diagnosisAntihyperglycemic drugsMedicare patientsDrug treatmentPatterns of usePatientsPackage inserts